Clinical Trial Detail

NCT ID NCT01543698
Title A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

colorectal cancer

Therapies

Binimetinib + Encorafenib

Binimetinib + Encorafenib + Ribociclib

Age Groups: adult

Additional content available in CKB BOOST